The FDA is considering a national registry for thermal ablation treatment of breast cancer. The proposed registry would compile information on all thermal ablation devices and therapies for small carcinomas and address inconsistencies that potentially diminish the value of previously published feasibility protocols.
The FDA is considering a national registry for thermal ablation treatment of breast cancer. The proposed registry would compile information on all thermal ablation devices and therapies for small carcinomas and address inconsistencies that potentially diminish the value of previously published feasibility protocols. It would also lay out standard protocols for tumor selection, biopsy techniques, pathology studies, image guidance, and postablation assessment.
The FDA described its rationale for a registry in the May 28 Federal Register. It will accept comments on the plan until Nov. 28.
Mammography and Breast MRI: Is it Time to Evaluate Strategies as Opposed to Modalities?
July 5th 2024The combination of mammography with breast MRI within 90 days had a 96.2 percent sensitivity in comparison to 48.1 percent for mammography and 79.7 percent for breast MRI performed within 91 to 270 days after index mammography, according to newly published research.
ACR Collaborative Model Leads to 35 Percent Improvement with Mammography Positioning Criteria
July 1st 2024Noting significant variation with facilities for achieving passing criteria for mammography positioning, researchers found that structured interventions, ranging from weekly auditing of images taken by technologists to mechanisms for feedback from radiologists to technologists, led to significant improvements in a multicenter study.